Long COVID Clusters of Symptoms Persist beyond Two Years after Infection: Insights from the CARDIO COVID 20-21 Registry.

Publication date: Jun 26, 2024

Long COVID presents with diverse symptoms after COVID-19. Different clusters of symptoms have been reported; however, their persistence beyond 2 years after COVID-19 remains unclear. In this cohort study, we prospectively evaluated individuals with previous severe COVID-19 presenting with long COVID at a two-year follow-up. We characterized the included patients and performed a cluster analysis of symptoms through multiple correspondence analysis and hierarchical clustering. A total of 199 patients with long COVID were included. The median age was 58 years (48-69), 56% were male, and the median follow-up time since the COVID-19 diagnosis was 26 months (IQR: 25, 27). Three symptom clusters were identified: Cluster 1 is characterized by fatigue, myalgia/arthralgia, a low prevalence of symptoms, and a lack of specific symptoms; Cluster 2 is defined by a high prevalence of fatigue, myalgia/arthralgia, and cardiorespiratory symptoms, including palpitations, shortness of breath, cough, and chest pain; and Cluster 3 is demonstrated a high prevalence of ageusia, anosmia, fatigue, and cardiorespiratory symptoms. Our study reinforces the concept of symptom clustering in long COVID, providing evidence that these clusters may persist beyond two years after a COVID-19 diagnosis. This highlights the chronic and debilitating nature of long COVID and the importance of developing strategies to mitigate symptoms in these patients.

Open Access PDF

Concepts Keywords
Cardiorespiratory Aged
Covid Ageusia
Male Anosmia
Months Arthralgia
Viruses cluster
Cluster Analysis
Cohort Studies
Cough
COVID-19
COVID-19
Dyspnea
Fatigue
Female
Follow-Up Studies
Humans
Latin America
long COVID
Male
Middle Aged
Myalgia
Post-Acute COVID-19 Syndrome
post-COVID condition
Prevalence
Prospective Studies
Registries
SARS-CoV-2
symptoms
Time Factors

Semantics

Type Source Name
disease MESH Long COVID
disease MESH Infection
disease MESH COVID-19
disease VO time
disease MESH symptom clusters
disease MESH arthralgia
disease VO LACK
disease MESH chest pain
disease IDO symptom
drug DRUGBANK Coenzyme M
disease VO organization
disease IDO history
disease MESH virus infection
disease MESH cognitive dysfunction
disease MESH diabetes mellitus
disease MESH encephalomyelitis
disease MESH postural orthostatic tachycardia syndrome
disease MESH cardiovascular diseases
disease MESH autoimmunity
disease VO organ
disease MESH inflammation
disease MESH thrombosis
disease IDO blood
disease VO Gap
disease MESH aids
disease MESH abnormalities
disease MESH Heart Failure
disease MESH Pulmonary Hypertension
disease MESH venous thromboembolism
disease MESH complications
disease MESH stroke
disease MESH pulmonary embolism
disease VO vaccination
disease MESH anorexia
disease MESH dysphagia
disease VO mouth
disease VO frequency
disease MESH hypertension
disease MESH overweight
disease MESH obesity
disease VO vaccine
disease VO dose
disease MESH reinfection
disease IDO country
disease MESH Dyslipidemia
disease MESH Asthma
pathway KEGG Asthma
disease MESH Atrial fibrillation
disease MESH edema
drug DRUGBANK Oxygen

Original Article

(Visited 3 times, 1 visits today)